Skip to main content
S&P 5007,729.77-0.18%DOW52,372.74-0.20%NASDAQ26,273.60-1.04%BTC$81,514.00+1.23%ETH$2,357.82+1.14%GOLD$4,032.00-0.48%OIL$100.19-2.52%
Smart Investors Daily
SID Premium
Treace Medical Concepts, Inc. logo

NASDAQ · TMCI

Treace Medical Concepts, Inc.

Healthcare · Medical - Devices

$4.83

Up+$0.39 (+8.07%)

Updated Oct 29, 2026, 3:34 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
183.56M
P/E ratio
-3.7
Dividend yield
0.00%
52-week range
$1.17 – $5.20
Volume
188.47K
Avg. volume
634.64K

Price performance · TMCI

TMCI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 28, 2026

TMCI closed at $4.83 after 21 trading sessions, up 8.78% for the selected period.

Last close
$4.83
Period change
+8.78%
Period low
$3.87
Period high
$4.83
Daily close
View OHLC price history
TMCI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 28, 2026$4.46$4.835$4.37$4.83188.47K
Oct 27, 2026$4.46$4.56$4.35$4.55180.89K
Oct 26, 2026$4.27$4.43$4.25$4.42157.21K
Oct 23, 2026$4.29$4.29$4.07$4.27213.11K
Oct 22, 2026$4.14$4.30$4.14$4.28250.32K
Oct 21, 2026$4.05$4.14$3.845$4.14196.64K
Oct 20, 2026$3.92$4.085$3.875$4.07184.22K
Oct 19, 2026$3.92$3.95$3.825$3.88144.29K
Oct 16, 2026$4.10$4.115$3.87$3.87131.74K
Oct 15, 2026$4.04$4.21$4.04$4.12261.91K
Oct 14, 2026$4.05$4.21$4.02$4.04220.33K
Oct 13, 2026$4.10$4.16$4.045$4.10112.19K
Oct 12, 2026$3.95$4.15$3.92$4.10124.31K
Oct 9, 2026$3.88$4.07$3.84$3.95161.17K
Oct 8, 2026$3.87$3.92$3.78$3.875233.8K
Oct 7, 2026$3.98$4.12$3.82$3.89250.35K
Oct 6, 2026$4.53$4.53$3.98$4.00652.13K
Oct 5, 2026$4.40$4.54$4.24$4.48210.75K
Oct 2, 2026$4.37$4.41$4.22$4.39154.67K
Oct 1, 2026$4.42$4.44$4.26$4.33183.06K
Sep 30, 2026$4.62$4.62$4.43$4.44157.61K

Latest TMCI news

The latest Smart Investors Daily articles mentioning TMCI.

Stock researchCompany · Overview

TMCI research

Overview

Company profile and research snapshot.

Company profile

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
TMCI recent ratings
DateFirmRatingTarget
Aug 10, 2026Truist SecuritiesHold—
Jul 16, 2026Truist SecuritiesHold—
Mar 2, 2026Lake StreetBuy—
Jan 7, 2026StifelHold—
Dec 18, 2025Truist SecuritiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group. Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using […]

Yahoo · Sep 17, 2026

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lap

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By